← Back to Search

Corticosteroid

Bupivacaine/triamcinolone injection for Cough

Phase 3

Recruiting

Research Sponsored by University of South Florida

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

Be older than 18 years old

Timeline

Screening 3 weeks

Treatment Varies

Follow Up immediately pre-treatment and post-treatment at 2 weeks

Awards & highlights

Study Summary

This study is evaluating whether a specific injection may help reduce coughing in individuals with neurogenic cough.

Eligible Conditions

Cough
Caudal Epidural Block Therapy

Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ immediately pre-treatment and post-treatment at 2 weeks

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~immediately pre-treatment and post-treatment at 2 weeks

This trial's timeline: 3 weeks for screening, Varies for treatment, and immediately pre-treatment and post-treatment at 2 weeks for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.

Primary outcome measures

2 week post-treatment cough severity index score improvement

2 week post-treatment cough-specific quality-of-life questionnaire score improvement

Secondary outcome measures

12 week post-treatment cough severity index score improvement

12 week post-treatment cough-specific quality-of-life questionnaire score improvement

6 week post-treatment cough severity index score improvement

+1 more

Trial Design

2Treatment groups

Experimental Treatment

Placebo Group

Group I: Bupivacaine/triamcinolone injectionExperimental Treatment1 Intervention

2-cc injection (mixture consisting of 1-cc of 0.5% Bupivacaine injection and 1cc of 40mg/cc triamcinolone acetonide suspension injection) will be delivered percutaneously into the region of the proximal superior laryngeal nerve, every 1-2 weeks, for total of 2 to 3 injections

Group II: Saline injectionPlacebo Group1 Intervention

2-cc injection of normal saline will be delivered percutaneously into the region of the proximal superior laryngeal nerve, every 1-2 weeks, for total of 2 to 3 injections

Do I qualify?Apply below to find out

Find a Location

Who is running the clinical trial?

University of South FloridaLead Sponsor

413 Previous Clinical Trials

188,202 Total Patients Enrolled

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

What are the main indications for Bupivacaine/triamcinolone injection?

"Bupivacaine/triamcinolone injection can help patients suffering from permphigus, lupus erythematosus cell, and ulcerative colitis."

Answered by AI

How many individuals are being tested in this experiment?

"Yes, the data on clinicaltrials.gov indicates that this study is currently seeking candidates. The clinical trial was initially posted on 1/12/2021 and was most recently edited on 11/6/2022. The study is recruiting for 65 participants between 1 locations."

Answered by AI

Is the Bupivacaine/triamcinolone injection procedure dangerous for patients?

"Bupivacaine/triamcinolone injection received a 3 because there is both some efficacy data and multiple rounds of safety data from Phase 3 trials."

Answered by AI

Are participants being enrolled in this clinical trial at this time?

"According to the latest update on clinicaltrials.gov, this trial is actively recruiting patients. The listing was first posted on 1/12/2021 and was last updated 11/6/2022."

Answered by AI

What are the goals that this research is hoping to achieve?

"The primary focus of this study will be cough-specific quality-of-life questionnaire score improvement at the 2 week mark post-treatment. However, secondary objectives monitored over a 12 week period include observing changes in cough severity index scores and quality-of-life questionnaire scores."

Answered by AI

Recent research and studies

clinicaltrials.govStudy

Randomized Placebo-controlled Analysis of Superior Laryngeal Nerve Block for Neurogenic Cough

Anthony Grady 2021. "Randomized Placebo-controlled Analysis of Superior Laryngeal Nerve Block for Neurogenic Cough". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT04468542.

All > Exparel